Contacts, documents and full notice history are available with a subscription.
Combined Synopsis/Solicitation NONE Expired 5 notices 7 documents

Structured Product Labeling (SPL) HT9426-26-Q-E022 PANDHA-26-P-0000035401

Solicitation PANDHA-26-P-0000035401 Copied Notice ID e923d4da864046738336d97877b911aa Copied DEPT OF DEFENSE — ARMY MED RES ACQ ACTIVITY
SAM.gov
Posted
Jun 29, 2026
Deadline
Jul 01, 2026
Set-aside
NONE
NAICS
541690
PSC
R408

Summary

AI-generated · May 21, 2026

Manage, process, and complete initial labeling and labeling changes in electronic Structured Product Label (SPL) submissions to the FDA. This work covers SPL submissions for two licensed NDA products, with up to five levels of primary and secondary labeling.

Structured Product Labeling (SPL) is an HL7 standard based on Clinical Document Architecture and HL7 Reference Information Model, accredited by ANSI for the exchange of product information. The engagement involves delivering SPL documentation and updates suitable for FDA submission and ensuring alignment with the SPL format and regulatory requirements.

Office of Regulated Activities of the DHA R&D Medical Research and Development Command (MRDC) has a requirement to manage, process, and complete initial labeling and labeling changes in electronic structured product label document submissions to the FDA. Structured Product Labeling (SPL) is a Health Level Seven (HL7) standard based on Clinical Document Architecture and HL7 Reference Information Model (RIM) accredited by the American National Standards Institute (ANSI) for the exchange of product information. The DHA R&D MRDC currently has 2 licensed New Drug Application (NDA) products which require SPL submissions for up to 5 levels of primary and secondary labeling.

From Combined Synopsis/Solicitation posted on May 20, 2026

Office of Regulated Activities of the DHA R&D Medical Research and Development Command (MRDC) has a requirement to manage, process, and complete initial labeling and labeling changes in electronic structured product label document submissions to the FDA. Structured Product Labeling (SPL) is a Health Level Seven (HL7) standard based on Clinical Document Architecture and HL7 Reference Information Model (RIM) accredited by the American National Standards Institute (ANSI) for the exchange of product information. The DHA R&D MRDC currently has 2 licensed New Drug Application (NDA) products which require SPL submissions for up to 5 levels of primary and secondary labeling.

From Combined Synopsis/Solicitation posted on Jun 05, 2026

Office of Regulated Activities of the DHA R&D Medical Research and Development Command (MRDC) has a requirement to manage, process, and complete initial labeling and labeling changes in electronic structured product label document submissions to the FDA. Structured Product Labeling (SPL) is a Health Level Seven (HL7) standard based on Clinical Document Architecture and HL7 Reference Information Model (RIM) accredited by the American National Standards Institute (ANSI) for the exchange of product information. The DHA R&D MRDC currently has 2 licensed New Drug Application (NDA) products which require SPL submissions for up to 5 levels of primary and secondary labeling.

From Combined Synopsis/Solicitation posted on Jun 10, 2026

Office of Regulated Activities of the DHA R&D Medical Research and Development Command (MRDC) has a requirement to manage, process, and complete initial labeling and labeling changes in electronic structured product label document submissions to the FDA. Structured Product Labeling (SPL) is a Health Level Seven (HL7) standard based on Clinical Document Architecture and HL7 Reference Information Model (RIM) accredited by the American National Standards Institute (ANSI) for the exchange of product information. The DHA R&D MRDC currently has 2 licensed New Drug Application (NDA) products which require SPL submissions for up to 5 levels of primary and secondary labeling.

From Combined Synopsis/Solicitation posted on Jun 23, 2026

Office of Regulated Activities of the DHA R&D Medical Research and Development Command (MRDC) has a requirement to manage, process, and complete initial labeling and labeling changes in electronic structured product label document submissions to the FDA. Structured Product Labeling (SPL) is a Health Level Seven (HL7) standard based on Clinical Document Architecture and HL7 Reference Information Model (RIM) accredited by the American National Standards Institute (ANSI) for the exchange of product information. The DHA R&D MRDC currently has 2 licensed New Drug Application (NDA) products which require SPL submissions for up to 5 levels of primary and secondary labeling.

From Combined Synopsis/Solicitation posted on Jun 29, 2026

Notice history

5
  1. Combined Synopsis/Solicitation Posted May 20, 2026 View
  2. Combined Synopsis/Solicitation Posted Jun 05, 2026
    • Response Deadline: Jun 05, 2026Jun 10, 2026
  3. Combined Synopsis/Solicitation Posted Jun 10, 2026
    • Response Deadline: Jun 10, 2026Jun 29, 2026
  4. Combined Synopsis/Solicitation Posted Jun 23, 2026
    • Response Deadline: Jun 29, 2026Jul 01, 2026
  5. Combined Synopsis/Solicitation LATEST Posted Jun 29, 2026
    No changes from previous notice

Details

Solicitation number PANDHA-26-P-0000035401
Notice ID e923d4da864046738336d97877b911aa
Notice type Combined Synopsis/Solicitation
Product / Service (PSC) R408
NAICS 541690
Set-aside No Set aside used
Place of performance Frederick, Maryland
Archive date Jul 16, 2026

Award Information

Not yet awarded

Contacts

primary
Matthew Gembe

Email

Phone

secondary
Terrie Bloom, Contracting Officer

Email

Agency

DEPT OF DEFENSE
DEFENSE HEALTH AGENCY (DHA)
ARMY MED RES ACQ ACTIVITY

Place of Performance

Frederick, Maryland 21702
USA

Dates

Posted Jun 29, 2026 1 month ago
Last Updated Aug 06, 2026 2 days ago
Due Jul 01, 2026 1 month ago